You are here

Articles

Drugs to Avoid in Patients on Tyrosine Kinase Inhibitors

published: 25 July 2014

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

published: 25 July 2014

Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia

published: 10 July 2014

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure

published: 10 July 2014

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

published: 8 July 2014

Managing children with chronic myeloid leukaemia (CML) Recommendations for the management of CML in children and young people up to the age of 18 years

published: 8 July 2014

Key Questions in CAR T-Cell Therapies

published: 20 June 2014

A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive onco-kinases

published: 20 June 2014

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

published: 9 June 2014

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

published: 15 May 2014

Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib

published: 15 May 2014

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

published: 8 May 2014

The impact of healthcare settings on survival time of patients with chronic myeloid leukemia Michael Lauseker

published: 4 April 2014

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study

published: 12 March 2014

Chronic Myeloid Leukemia: 2013 American Society of Hematology Annual Meeting*

published: 4 March 2014

Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

published: 11 February 2014

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

published: 31 January 2014

ARIAD Announces the Commercial Availability of Iclusig (Ponatinib) for Patients with Refractory Philadelphia-Positive Leukemias in the U.S.

published: 17 January 2014

Bone Marrow Microenvironment Could Offer Future Target in CML

published: 9 January 2014

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

published: 2 January 2014